Cargando…

Advanced glycation end products inhibit the osteogenic differentiation potential of adipose‐derived stem cells by modulating Wnt/β‐catenin signalling pathway via DNA methylation

OBJECTIVES: Advanced glycation end products (AGEs) are considered a cause of diabetic osteoporosis. Although adipose‐derived stem cells (ASCs) are widely used in the research of bone regeneration, the mechanisms of the osteogenic differentiation of ASCs from diabetic osteoporosis model remain unclea...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yong, Wang, Lang, zhang, Maorui, Huang, Kui, Yao, Zhihao, Rao, Pengcheng, Cai, Xiaoxiao, Xiao, Jingang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309593/
https://www.ncbi.nlm.nih.gov/pubmed/32468637
http://dx.doi.org/10.1111/cpr.12834
_version_ 1783549236908916736
author Li, Yong
Wang, Lang
zhang, Maorui
Huang, Kui
Yao, Zhihao
Rao, Pengcheng
Cai, Xiaoxiao
Xiao, Jingang
author_facet Li, Yong
Wang, Lang
zhang, Maorui
Huang, Kui
Yao, Zhihao
Rao, Pengcheng
Cai, Xiaoxiao
Xiao, Jingang
author_sort Li, Yong
collection PubMed
description OBJECTIVES: Advanced glycation end products (AGEs) are considered a cause of diabetic osteoporosis. Although adipose‐derived stem cells (ASCs) are widely used in the research of bone regeneration, the mechanisms of the osteogenic differentiation of ASCs from diabetic osteoporosis model remain unclear. This work aimed to investigate the influence and the molecular mechanisms of AGEs on the osteogenic potential of ASCs. MATERIALS AND METHODS: Enzyme‐linked immunosorbent assay was used to measure the change of AGEs in diabetic osteoporotic and control C57BL/6 mice. ASCs were obtained from the inguinal fat of C57BL/6 mice. AGEs, 5‐aza2′‐deoxycytidine (5‐aza‐dC) and DKK‐1 were used to treat ASCs. Real‐time cell analysis and cell counting kit‐8 were used to monitor the proliferation of ASCs within and without AGEs. Real‐time PCR, Western blot and Immunofluorescence were used to analyse the genes and proteins expression of osteogenic factors, DNA methylation factors and Wnt/β‐catenin signalling pathway among the different groups. RESULTS: The AGEs and DNA methylation were increased in the adipose and bone tissue of the diabetic osteoporosis group. Untreated ASCs had higher cell proliferation activity than AGEs‐treatment group. The expression levels of osteogenic genes, Opn and Runx2, were lower, and mineralized nodules were less in AGEs‐treatment group. Meanwhile, DNA methylation was increased, and the Wnt signalling pathway markers, including β‐Catenin, Lef1 and P‐GSK‐3β, were inhibited. After treatment with 5‐aza‐dC, the osteogenic differentiation capacity of ASCs in the AGEs environment was restored and the Wnt signalling pathway was activated during this process. CONCLUSIONS: Advanced glycation end products inhibit the osteogenic differentiation ability of ASCs by activating DNA methylation and inhibiting Wnt/β‐catenin pathway in vitro. Therefore, DNA methylation may be promising targets for the bone regeneration of ASCs with diabetic osteoporosis.
format Online
Article
Text
id pubmed-7309593
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73095932020-06-24 Advanced glycation end products inhibit the osteogenic differentiation potential of adipose‐derived stem cells by modulating Wnt/β‐catenin signalling pathway via DNA methylation Li, Yong Wang, Lang zhang, Maorui Huang, Kui Yao, Zhihao Rao, Pengcheng Cai, Xiaoxiao Xiao, Jingang Cell Prolif Original Articles OBJECTIVES: Advanced glycation end products (AGEs) are considered a cause of diabetic osteoporosis. Although adipose‐derived stem cells (ASCs) are widely used in the research of bone regeneration, the mechanisms of the osteogenic differentiation of ASCs from diabetic osteoporosis model remain unclear. This work aimed to investigate the influence and the molecular mechanisms of AGEs on the osteogenic potential of ASCs. MATERIALS AND METHODS: Enzyme‐linked immunosorbent assay was used to measure the change of AGEs in diabetic osteoporotic and control C57BL/6 mice. ASCs were obtained from the inguinal fat of C57BL/6 mice. AGEs, 5‐aza2′‐deoxycytidine (5‐aza‐dC) and DKK‐1 were used to treat ASCs. Real‐time cell analysis and cell counting kit‐8 were used to monitor the proliferation of ASCs within and without AGEs. Real‐time PCR, Western blot and Immunofluorescence were used to analyse the genes and proteins expression of osteogenic factors, DNA methylation factors and Wnt/β‐catenin signalling pathway among the different groups. RESULTS: The AGEs and DNA methylation were increased in the adipose and bone tissue of the diabetic osteoporosis group. Untreated ASCs had higher cell proliferation activity than AGEs‐treatment group. The expression levels of osteogenic genes, Opn and Runx2, were lower, and mineralized nodules were less in AGEs‐treatment group. Meanwhile, DNA methylation was increased, and the Wnt signalling pathway markers, including β‐Catenin, Lef1 and P‐GSK‐3β, were inhibited. After treatment with 5‐aza‐dC, the osteogenic differentiation capacity of ASCs in the AGEs environment was restored and the Wnt signalling pathway was activated during this process. CONCLUSIONS: Advanced glycation end products inhibit the osteogenic differentiation ability of ASCs by activating DNA methylation and inhibiting Wnt/β‐catenin pathway in vitro. Therefore, DNA methylation may be promising targets for the bone regeneration of ASCs with diabetic osteoporosis. John Wiley and Sons Inc. 2020-05-28 /pmc/articles/PMC7309593/ /pubmed/32468637 http://dx.doi.org/10.1111/cpr.12834 Text en © 2020 The Authors. Cell Proliferation published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Li, Yong
Wang, Lang
zhang, Maorui
Huang, Kui
Yao, Zhihao
Rao, Pengcheng
Cai, Xiaoxiao
Xiao, Jingang
Advanced glycation end products inhibit the osteogenic differentiation potential of adipose‐derived stem cells by modulating Wnt/β‐catenin signalling pathway via DNA methylation
title Advanced glycation end products inhibit the osteogenic differentiation potential of adipose‐derived stem cells by modulating Wnt/β‐catenin signalling pathway via DNA methylation
title_full Advanced glycation end products inhibit the osteogenic differentiation potential of adipose‐derived stem cells by modulating Wnt/β‐catenin signalling pathway via DNA methylation
title_fullStr Advanced glycation end products inhibit the osteogenic differentiation potential of adipose‐derived stem cells by modulating Wnt/β‐catenin signalling pathway via DNA methylation
title_full_unstemmed Advanced glycation end products inhibit the osteogenic differentiation potential of adipose‐derived stem cells by modulating Wnt/β‐catenin signalling pathway via DNA methylation
title_short Advanced glycation end products inhibit the osteogenic differentiation potential of adipose‐derived stem cells by modulating Wnt/β‐catenin signalling pathway via DNA methylation
title_sort advanced glycation end products inhibit the osteogenic differentiation potential of adipose‐derived stem cells by modulating wnt/β‐catenin signalling pathway via dna methylation
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309593/
https://www.ncbi.nlm.nih.gov/pubmed/32468637
http://dx.doi.org/10.1111/cpr.12834
work_keys_str_mv AT liyong advancedglycationendproductsinhibittheosteogenicdifferentiationpotentialofadiposederivedstemcellsbymodulatingwntbcateninsignallingpathwayviadnamethylation
AT wanglang advancedglycationendproductsinhibittheosteogenicdifferentiationpotentialofadiposederivedstemcellsbymodulatingwntbcateninsignallingpathwayviadnamethylation
AT zhangmaorui advancedglycationendproductsinhibittheosteogenicdifferentiationpotentialofadiposederivedstemcellsbymodulatingwntbcateninsignallingpathwayviadnamethylation
AT huangkui advancedglycationendproductsinhibittheosteogenicdifferentiationpotentialofadiposederivedstemcellsbymodulatingwntbcateninsignallingpathwayviadnamethylation
AT yaozhihao advancedglycationendproductsinhibittheosteogenicdifferentiationpotentialofadiposederivedstemcellsbymodulatingwntbcateninsignallingpathwayviadnamethylation
AT raopengcheng advancedglycationendproductsinhibittheosteogenicdifferentiationpotentialofadiposederivedstemcellsbymodulatingwntbcateninsignallingpathwayviadnamethylation
AT caixiaoxiao advancedglycationendproductsinhibittheosteogenicdifferentiationpotentialofadiposederivedstemcellsbymodulatingwntbcateninsignallingpathwayviadnamethylation
AT xiaojingang advancedglycationendproductsinhibittheosteogenicdifferentiationpotentialofadiposederivedstemcellsbymodulatingwntbcateninsignallingpathwayviadnamethylation